Quantitation of  autophagic flux  in mature skeletal muscle by Ju, Jeong-Sun et al.
Washington University School of Medicine
Digital Commons@Becker
Open Access Publications
2010
Quantitation of "autophagic flux" in mature skeletal
muscle
Jeong-Sun Ju
Washington University School of Medicine in St. Louis
Arun S. Varadhachary
Washington University School of Medicine in St. Louis
Sara E. Miller
Washington University School of Medicine in St. Louis
Conrad C. Weihl
Washington University School of Medicine in St. Louis
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Ju, Jeong-Sun; Varadhachary, Arun S.; Miller, Sara E.; and Weihl, Conrad C., ,"Quantitation of "autophagic flux" in mature skeletal
muscle." Autophagy.6,7. 929-935. (2010).
https://digitalcommons.wustl.edu/open_access_pubs/2789
www.landesbioscience.com Autophagy 929
Autophagy 6:7, 929-935; October 1, 2010; © 2010 Landes Bioscience
TOOLBOx TOOLBOx
Key words: autophagy, rapamycin,  
skeletal muscle
Submitted: 04/07/10
Revised: 06/22/10
Accepted: 06/24/10
Previously published online: 
www.landesbioscience.com/journals/
autophagy/article/12785
DOI: 10.4161/auto.6.7.12785
*Correspondence to: Conrad Weihl; 
Email: weihlc@neuro.wustl.edu
Reliable and quantitative assays to measure in vivo autophagy are essen-
tial. Currently, there are varied methods 
for monitoring autophagy; however, 
it is a challenge to measure “autopha-
gic flux” in an in vivo model system. 
Conversion and subsequent degradation 
of the microtubule-associated protein 1 
light chain 3 (MAP1-LC3/LC3) to the 
autophagosome associated LC3-II iso-
form can be evaluated by immunoblot. 
However, static levels of endogenous 
LC3-II protein may render possible mis-
interpretations since LC3-II levels can 
increase, decrease or remain unchanged 
in the setting of autophagic induction. 
Therefore, it is necessary to measure 
LC3-II protein levels in the presence 
and absence of lysomotropic agents that 
block the degradation of LC3-II, a tech-
nique aptly named the “autophagom-
eter.” In order to measure autophagic 
flux in mouse skeletal muscle, we treated 
animals with the microtubule depolar-
izing agent colchicine. Two days of 0.4 
mg/kg/day intraperitoneal colchicine 
blocked autophagosome maturation to 
autolysosomes and increased LC3-II pro-
tein levels in mouse skeletal muscle by 
>100%. The addition of an autophagic 
stimulus such as dietary restriction or 
rapamycin led to an additional increase 
in LC3-II above that seen with colchi-
cine alone. Moreover, this increase was 
not apparent in the absence of a “colchi-
cine block.” Using this assay, we evalu-
ated the autophagic response in skeletal 
muscle upon denervation induced atro-
phy. Our studies highlight the feasibility 
of performing an “in vivo autophagom-
eter” study using colchicine in skeletal 
muscle.
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Introduction
Autophagy is a nonspecific and bulk 
degradation process which delivers cyto-
plasmic materials including damaged 
organelles, toxic protein aggregates and 
intracellular pathogens to lysosomes via 
double-membraned organelles termed 
autophagosomes.1 Autophagy is highly 
dynamic and regulated. Autophagic activ-
ity is usually low under basal conditions, 
but can be markedly increased by stimuli 
such as nutrient deprivation, hypoxia, cel-
lular stress, infection and pharmacologi-
cal agents such as rapamycin. Defects in 
autophagy are associated with a number 
of disorders, including cancer, neurode-
generation, muscle disease and inflam-
mation. There is a rapidly growing need 
among scientists to have tools and assays 
that allow one to accurately detect auto-
phagy and study its function in mam-
malian systems.2,3 LC3 is a ubiquitin-like 
molecule that is conjugated to phosphati-
dylethanolamine by Atg7 to form LC3-II 
upon autophagic stimulation.1 LC3-II is 
localized to autophagic structures includ-
ing phagophores, autophagosomes and 
autolysosomes. Cellular LC3-II levels cor-
relate with autophagosome number and 
measuring the conversion of LC3-I to 
LC3-II by immunoblot is a reliable assay 
for autophagosome formation.3 However, 
there are limitations to the interpretation 
of LC3-II levels since LC3-II is both pro-
duced and degraded during autophagy. To 
circumvent this, it has been proposed that 
LC3-II levels should only be evaluated 
in the presence and absence of inhibitors 
which block autophagosome and hence 
LC3-II degradation.2,4 This method has 
become the mainstay of LC3-II analysis 
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chloroquine, 0.4 mg/kg/day colchicine or 
2 mg/kg/day vinblastine for two days and 
then isolated tibialis anterior (TA) muscle. 
No weight loss or distress was seen after 
two days treatment with any of the three 
drugs. Moreover, there was no evidence of 
myopathic features or vacuolization in the 
skeletal muscle by routine histopathology 
(not shown). The TA was homogenized 
and the resultant lysate was subjected to 
SDS-PAGE and immunoblotted with an 
antibody to LC3. The levels of LC3-II 
were significantly elevated in the colchi-
cine and vinblastine treated mice (Fig. 
1A). This increase in LC3-II correlated 
with a significant increase in LC3 positive 
puncta as demonstrated in untreated com-
pared with 2-day colchicine-treated mouse 
skeletal muscle via immunhistochemistry 
using an LC3 specific antibody (Fig. 1B). 
p62 levels were unchanged at this same 
timepoint (see colchicine-treated animals 
from blots in Figs. 2A, 3A and D). Longer 
treatments with all three drugs resulted in 
only a modest further increase in LC3-II 
levels and significantly increased levels of 
p62 (not shown). In addition, longer treat-
ment with vinblastine and chloroquine 
resulted in significantly more animal 
toxicity with weight loss and death after 
5–7 days. This was not seen with chronic 
colchicine treatment for an additional 10 
days (longest time point evaluated). The 
addition of vinblastine or chloroquine to 
i.p. colchicine treatment was also not tol-
erated by the animals.
To confirm that colchicine treatment 
did indeed block autophagosome deg-
radation (i.e., fusion of the autophago-
some with the lysosome), we utilized a 
tandemly tagged mCherry-GFP-LC3 
reporter construct.6 This reporter fluo-
resces green and red in the neutral envi-
ronment of an autophagosome and red 
in the acidic environment of an autol-
ysosome or other acidic organelle. This 
construct was electroporated into the TA 
muscle of 3-month-old male mice and 
allowed to express for seven days. On 
day 5, mice were treated with saline or 
0.4 mg/kg i.p. colchicine for two days. 
TA muscle was harvested and sectioned. 
Untreated mouse muscle had diffuse 
green and red fluorescence throughout 
the myofiber with no visible puncta as 
would be expected for an LC3 protein 
muscle and provides examples of the util-
ity of this assay.
Results
Chronic intoxication of patients and mice 
with chloroquine, colchicine or vinblas-
tine results in similar vacuolar myopa-
thies.5 The pathogenic mechanism is 
presumed to be a decrease in lysosomal 
protein degradation secondary to impaired 
autophagosome-lysosome fusion, dimin-
ished delivery of proteolytic enzymes to 
the lysosome or deacidification of the lyso-
some. We reasoned that these drugs may 
be able to effectively block autophagosome 
degradation in vivo. With this premise, we 
treated 3-month-old male mice with intra-
peritoneal (i.p.) vehicle, 50 mg/kg/day 
in cell culture models and is discussed in 
detail in several review papers.2,4
In order to adapt this technique to an 
in vivo mammalian model such as mice, 
we screened several lysomotropic and/or 
autophagosome-lysosome fusion inhibi-
tors for their ability to increase basal 
LC3-II protein levels in mouse skeletal 
muscle. These preliminary studies identi-
fied colchicine as a safe, quick-acting and 
potent compound that increased LC3-II 
levels >100%. In vivo blockage of LC3-II 
degradation with colchicine enabled us 
to quantitate the induction of autophagy 
following nutrient deprivation or with the 
mTOR inhibitors rapamycin and temsiro-
limus in mature skeletal muscle. The fol-
lowing manuscript details how to measure 
in vivo autophagic flux in mouse skeletal 
Figure 1. (A) 3-month-old male mice were treated with vehicle, 50 mg/kg/day chloroquine, 0.4 
mg/kg/day colchicine or 2 mg/kg/day vinblastine for two days and tibialis anterior (TA) muscle 
lysates were evaluated by LC3 immunoblot. Actin is shown as a loading control. Blot is represen-
tative of 3 independent experiments. (B) TA from similarly treated mice as in (A) was subjected 
to immunofluorescence using an LC3 antibody. Colchicine treated mice had an increase in LC3 
positive puncta. Images were taken at the same camera setting and exposure time. Scale is 40 
mM. (C) The TA muscle from 3-month-old male mice was electroporated with a tandemly tagged 
mCherry-GFP-LC3 reporter construct. Mice were either treated for two days with vehicle or 0.4 
mg/kg/day colchicine. Vehicle treated mice had diffuse LC3 fluorescence while colchicine treated 
mice generated GFP and mCherry positive co-localizing puncta consistent with colchicine impair-
ing autophagosome maturation to an acidic organelle. Scale is 25 mM.
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whether autophagic flux was upregulated 
after seven days neurogenic atrophy. To do 
this, we performed a sham or complete sci-
atic nerve transaction in several cohorts of 
mice treated with and without colchicine 
for two days (Fig. 4A, outlines experimen-
tal design). Denervation-induced atrophy 
was confirmed via routine muscle histo-
pathology and showed multiple atrophic 
angular fibers as compared to sham con-
trols (Fig. 4B). TA muscle was harvested 
seven days post-denervation. Some groups 
received colchicine for two days prior to 
animal sacrifice. With this strategy, we 
confirmed that autophagy is upregulated 
as assessed by an increase in LC3-I and 
LC3-II levels and further established that 
“autophagic flux” is increased in denerva-
tion-induced atrophy at seven days (Fig. 
4C and D).
with 10 mg/kg/day i.p. rapamycin (Fig. 
3B and C). This was similar to that seen 
when mice were treated for 7 days with 
20 mg/kg/day of the rapamycin ana-
log, temsirolimus/CCI-779 (Fig. 3D). 
Interestingly, in both cases the increase 
in LC3-II was not apparent without the 
addition of colchicine for two days. As 
expected both rapamycin and temsiroli-
mus were able to decrease the phosphory-
lation of ribosomal protein S6 consistent 
with their primary effect on the mTOR 
pathway (Fig. 3B and D).
We wondered if the in vivo autopha-
gic flux assay would be able to answer 
whether autophagy is activated in skel-
etal muscle following denervation. It has 
been previously reported that autophagy 
is upregulated late in denervation-induced 
atrophy.7,8 Therefore, we evaluated 
that is not present on an autophagic struc-
ture (Fig. 1C). In contrast, two days of 
colchicine treatment generated myofibers 
with multiple dual fluorescing GFP and 
mCherry positive puncta consistent with 
autophagosomes that have not matured 
to autolysosomes and become acidified 
(Fig. 1C). In nonelectroporated myofi-
bers, colchicine induced more LC3 posi-
tive puncta than Lamp2 positive puncta 
and LC3 and Lamp2 did not co-localize 
(not shown). These data further support 
that two days of 0.4 mg/kg i.p. colchicine 
is able to block autophagosome degrada-
tion in mouse skeletal muscle and this 
dose was employed for all subsequent 
experiments.
To see if the addition of colchicine 
would allow us to quantitate autophagic 
flux in vivo, we induced autophagy in mice 
by depriving them of food for two days. 
Four different cohorts of mice were used 
(untreated, colchicine treated, starved 
and starved plus colchicine treated) and 
TA, gastrocnemius and quadriceps muscle 
were harvested. Starved mice lost >10% of 
their body weight over the two-day period 
confirming that they were in fact nutrient 
deprived. Muscle lysates were subjected 
to SDS-PAGE and LC3 immunoblot. 
Consistent with our previous experiment, 
colchicine treatment increased the level 
of LC3-II by >100%. Starvation alone 
did not significantly increase LC3-II lev-
els; however, starvation plus colchicine 
increased LC3-II levels above that seen 
with colchicine alone in all three muscles 
(Fig. 2A and B and not shown).
It was previously reported that the 
mTOR inhibitor rapamycin only mod-
estly enhanced autophagy in cultured 
myotubes.7 We confirmed this find-
ing in differentiated C2C12 myotubes 
using an in vitro autophagic flux assay. 
Differentiated C2C12 cells were treated 
with 10 mg/mL rapamycin and rapamy-
cin with 200 nM bafilomycinA1. At this 
dose of rapamycin we inhibited mTOR as 
assessed by the phosphorylation of ribo-
somal protein S6 in myotubes, and slightly 
increased the levels of LC3-II above that 
seen with bafilomycinA1 alone (Fig. 3A). 
In contrast, the corollary experiment done 
in vivo with a colchicine “block” demon-
strated a significant increase in LC3-II 
when mice were treated for seven days 
Figure 2. (A) Similar mice were treated with vehicle, 0.4 mg/kg/day colchicine, nutrient depriva-
tion (starvation) or nutrient deprivation plus 0.4 mg/kg/day colchicine for two days. TA muscle 
lysates were evaluated by LC3 and p62 immunoblot. Note that colchicine treatment significantly 
increases LC3-II levels. These levels are augmented by nutrient deprivation. Blot is representative 
of three independent experiments. (B) LC3-II/actin ratios were quantitated via densitometry from 
six mice per treatment condition. Error bars represent standard error and **denote p values of 
<0.005 as obtained by student paired t-test.
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treatment of mice with colchicine (>five 
days) did lead to an increase in p62 pro-
tein levels (not shown). Perhaps the dif-
ferential accumulation of LC3-II versus 
p62 under conditions of autophagic block 
highlights the distinct autophagic degra-
dation kinetics of these two substrates in 
mature skeletal muscle as compared to cell 
culture. For example, p62 associates with 
myofibrillar proteins such as titin and may 
turnover more slowly than LC3-II.9
Another critical difference between an 
in vitro and in vivo autophagic flux assay 
is the time period of bafilomycinA1 versus 
colchicine treatment. Whereas in cultured 
cells one can treat with bafilomycinA1 for 
short periods of time (e.g., 2–4 hours) and 
achieve a block in autophagosome-lyso-
some fusion, this is not feasible in vivo. It is 
conceivable that the prolonged use of col-
chicine to block autophagosome-lysosome 
fusion in vivo compensatorily leads to an 
upregulation in autophagy. However, this 
does not seem to be apparent at two days 
since there is no increase in LC3-I levels. 
Both LC3-I and LC3-II levels are elevated 
“blocking” agents. Therefore the inter-
pretation of any result using colchicine in 
vivo should consider the possibility that an 
increase in LC3-II levels is secondary to 
an additional blockage in autophagosome 
maturation or lysosomal degradation. It is 
important to note that nutrient depriva-
tion and mTOR inhibition via rapamycin 
or temsirolimus alone failed to increase the 
levels of LC3-II suggesting that autopha-
gic flux is not impaired by these treat-
ments. In these instances colchicine did 
not result in an additive effect (as would 
be expected if starvation or rapamycin 
resulted in a decrease in autophagic flux) 
but instead colchicine treatment revealed 
an increase in autophagic flux that was not 
readily apparent with rapamycin or starva-
tion alone.
It is notable that p62 levels were 
unchanged following two days of in vivo 
colchicine treatment whereas LC3-II lev-
els significantly increased. This difference 
was not seen in bafilomycinA1 treated 
myotubes where both p62 and LC3-II lev-
els increased similarly (Fig. 3A). Chronic 
Discussion
We describe an in vivo autophagic flux 
assay that uses colchicine to block autopha-
gosome degradation in skeletal muscle. 
Although the principles of the assay have 
been described for cell culture,2,4 this 
report broadens the utility of an autopha-
gic flux assay to whole animal models. 
Several key differences in these assays war-
rant further discussion. One necessary ele-
ment of the in vitro autophagic flux assay is 
that autophagosome degradation must be 
completely blocked. It has been suggested 
that bafilomycinA1 or other lysomotropic 
agent be carefully titrated in vitro and that 
different cell lines may require different 
doses.4 Moreover, the addition of a sec-
ond agent such as vinblastine to the opti-
mal established dose of bafilomycinA1 
can help confirm a complete “block” in 
LC3-II degradation.4 We attempted this 
in vivo. However, increasing doses of col-
chicine above 0.6 mg/kg/day had lethal 
consequences as did the addition of other 
Figure 3. (A) Differentiated C2C12 myotubes were treated with vehicle, 200 nM BafilomycinA1, 10 mg/mL rapamycin or 10 mg/mL rapamycin plus  
200 nM BafilomycinA1 for 6 hours. Lysates were subjected to LC3 and p62 immunoblots. Rapamycin did not increase LC3-II levels further than that 
seen with BafilomycinA1 alone. The same lysates were subjected to immunoblot with antibodies to phospho-S6 (Ser235/236) and S6 kinase demon-
strating that rapamycin is capable of mTOR inhibition in these cells. Blot is representative of two independent experiments. (B) 3-month-old male mice 
were treated with vehicle, 0.4 mg/kg/day colchicine for two days, 10 mg/kg/day rapamycin for 7 days or 10 mg/kg/day rapamycin for 7 days and 0.4 
mg/kg/day colchicine for two days beginning on day 5 and TA lysates were subjected to immunoblotting with LC3, p62, phospho-S6, total S6 kinase or 
actin. Blot is representative of four independent experiments. (C) LC3-II/actin ratios were quantitated via densitometry from eight mice per treatment 
condition. Error bars represent standard error and **denote p values of <0.005 as obtained by student paired t-test. (D) A similar experiment to (B) 
was performed using 20 mg/kg/day temsirolimus/CCI-779 instead of rapamycin. Note that the addition of temsirolimus/CCI-779 to colchicine further 
increased LC3-II levels consistent with an enhancement in autophagic flux.
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a reversible vacuolar myopathy.5 Muscle 
tissue from colchicine myopathy patients 
characteristically contains vacuoles that 
label with acid hydrolases suggesting that 
they are lysosomal in origin.5 This suggests 
that skeletal muscle may be particularly 
sensitive to the autophagosome-lysosome 
fusion effects of colchicine.
Our in vivo autophagic flux assay was 
able to detect an increase in autophagy 
following seven days of treatment with 
the mTOR inhibitors rapamycin or tem-
sirolimus. Previously it had not been well 
established that these drugs were able 
to stimulate autophagic flux in skeletal 
muscle. In fact it had been suggested that 
rapamycin was not a potent activator of 
autophagy in skeletal muscle.7 Our data 
would suggest that mTOR inhibition can 
activate autophagy similar to that seen 
with nutrient deprivation. This data raises 
the possibility that an in vivo autophagic 
flux may validate the efficacy of auto-
phagy enhancing drugs that fail to signifi-
cantly induce autophagy in vitro. Finally, 
our assay was able to detect an increase 
in autophagic flux following denervation 
induced atrophy. Consistent with previous 
reports looking at LC3-II protein levels 
and autophagy related transcript changes, 
we found that autophagy was activated 
after seven days of denervation.7,8 This 
finding further validates the utility of our 
in vivo autophagic flux assay.
bafilomycinA1 and vinblastine which 
have significant toxicities; and (3) the 
increase in LC3-II protein levels occurred 
rapidly in skeletal muscle within two 
days of colchicine treatment. Colchicine 
inhibits microtubule polymerization by 
binding to tubulin.5 This mechanism of 
action has led to its use as a chemothera-
peutic and anti-inflammatory agent since 
it targets dividing cells and can inhibit 
neutrophil motility. Chronic treatment of 
mice or patients with colchicine can cause 
when mice are treated with colchicine 
beyond five days suggesting that both an 
enhancement and blockage of autophagy 
is occurring with prolonged treatment 
(not shown).
One important aspect of this assay 
is the use of colchicine as a blocker of 
autophagosome degradation. We selected 
colchicine for several reasons. (1) colchi-
cine is inexpensive and has excellent in 
vivo pharmokinetics; (2) colchicine is 
well tolerated by mice unlike chloroquine, 
Figure 4. Denervation-induced atrophy 
enhances autophagic flux. (A) Schematic of 
experimental design to assess autophagic 
flux post denervation. Briefly, 3-month-old 
male mice had a sham or complete sciatic 
nerve transaction (denervation) for seven 
days prior to muscle harvesting. Mice were 
also treated with vehicle or 0.4 mg/kg/day 
colchicine for two days prior to harvesting. 
(B) Hematoxylin and eosin staining of TA 
muscle from 7 day sham or denervated mice. 
Note an increase in atrophic angular fibers in 
denervated animal (arrows). Scale is 40 mM. 
(C) TA muscle lysates from each group were 
subjected to LC3, p62 or actin immunoblots. 
Blots are representative of two independent 
experiments. There was an augmentation of 
LC3-II levels above that seen with colchi-
cine alone after seven days of denervation. 
(D) LC3-II/actin ratios were quantitated via 
densitometry from muscle lysates from two 
independent experiments with two mice per 
treatment condition. Error bars represent 
standard error and *denote p values of <0.05 
as obtained by student paired t-test.
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containing protease inhibitor cocktail 
(Sigma-Aldrich) with glass grinding tubes 
resting in an ice-water bath. The skeletal 
muscle homogenate was then centrifuged 
at 10,000 g for 10 min at 4°C. The pro-
tein concentration of the supernatant 
was quantitated using the bicinchoninic 
acid kit (Pierce Chemical; 23225) with 
BSA as a standard and adjusted to 2 mg/
ml in RIPA buffer. This yields 800–1,000 
mL of lysate. Aliquots of the lysate were 
further solubilized in Laemmli sample 
buffer and boiled for 5 min prior to SDS-
PAGE. 50 mg of protein was loaded and 
resolved on 12% SDS-PAGE gels. Gel was 
transferred to nitrocellulose membranes 
(Trans-Blot, Bio-Rad) and the membrane 
was blocked in a solution of 5% nonfat 
dry milk in Tris-buffered saline contain-
ing 0.5% Tween-20 (TBS-T). Membranes 
were incubated with a 1:2,000 dilution of 
LC3B antibody in 1% milk and TBS-T, a 
1:2,500 dilution of anti-p62 antibody, or 
a 1:5,000 dilution of anti-actin antibody. 
Blots were subsequently incubated with 
peroxidase-conjugated secondary anti-
bodies and immunoreactive proteins were 
revealed using the ECL detection system 
(GE Healthcare; RPN2209). Western 
blot results were quantified by densito-
metric analysis using ImageJ software 
(NIH). Western blots for phosphorylated 
(Ser235/236) and p70 S6K were per-
formed by a method analogous to that 
described above.
Cell culture. The mouse myoblast 
cell line C2C12 (American Type Culture 
Collection) was maintained at 37°C in 
5% CO
2
 in Dulbecco’s modified Eagle 
Medium (GIBCO; 11965) supplemented 
with 10% fetal bovine serum, 50 mg/ml 
penicillin and 50 mg/ml streptomycin. 
Cultures were induced to differentiate in 
DMEM containing 2% horse serum for 
five days. C2C12 myotubes grown on 
six-well plates were treated with 10 mg/
mL rapamycin with and without 200 
nM BafilomycinA1 for 6 hours. Cells 
were washed with ice-cold PBS and then 
scraped into RIPA buffer. Lysates were 
centrifuged at 10,000 g for 10 min. All 
western blots of C2C12 cells were pro-
cessed in an analogous manner as mouse 
muscle tissues and 20 mg of total proteins 
were subjected to SDS-PAGE.
P36931). Specimens were examined using 
a fluorescent microscope (Nikon 80i 
upright) and Roper Scientific EZ mono-
chrome CCD camera with deconvolution 
software analysis (NIS Elements, Nikon). 
Nonfluorescent images were taken with a 
5 megapixel color CCD (Nikon). Image 
processing and analysis were done with 
(NIS Elements 4.0) software and Adobe 
Photoshop CS3. All images were per-
formed at room temperature using a 40X 
objective.
Activation and blocking autophagy 
in vivo. All animal experimental proto-
cols were approved by the Animal Studies 
Committee of Washington University 
School of Medicine. Male C57BL6/J mice 
(Jackson Laboratory) at 11∼12 weeks of 
age were used for all experiments. Upon 
arrival to Washington University School 
of Medicine, mice were housed in a tem-
perature-controlled environment with 12 
hr light/dark cycles where they received 
food and water ad libitum for a minimum 
of 72 hours prior to any experimentation. 
Rapamycin and temsirolimus were dis-
solved in 100% ethanol for a 62.5 mg/
ml stock solution and stored at -20°C. 
Immediately prior to injection, rapamycin 
and temsirolimus were diluted to 2.5 mg/
ml in vehicle solution (5% PEG 400, 5% 
Tween 80 and 4% ethanol). 10 mg/kg/day 
rapamycin, 20 mg/kg/day temsirolimus or 
vehicle was i.p. injected to mice daily for 
seven days. Nutrient deprivation was per-
formed by removing food for 48 hr. Mice 
had free access to drinking water. Mice 
were weighed daily to confirm starvation. 
0.4 mg/kg/day colchicine was dosed i.p. 
in the last two days of the experiment. 
Colchicine was dissolved in water and 
stored at -20°C as a stock solution at a con-
centration of 4 mg/ml. On the day of treat-
ment, colchicine was diluted to 0.1 mg/ml 
in water prior to injection. Control mice 
received an equal volume of i.p. water.
Western blot of muscle tissue. Animals 
were anesthetized with an i.p. injection of 
pentobarbital sodium (0.5 mg/kg) and 
skeletal muscle was immediately dissected 
and flash frozen in liquid nitrogen. Frozen 
muscle was homogenized in 1 mL ice-
cold RIPA buffer (150 mM NaCl; 10 mM 
Tris-HCl, pH 7.2; 0.1% Triton X-100; 
1% sodium deoxycholate; 5 mM EDTA) 
Materials and Methods
Reagents and antibodies. Rapamycin 
(R-5000) and Temsirolimus/CCI-
779 (T-8040) were purchased from 
LC Laboratories (www.LCLabs.com). 
BafilomycinA1 (B1793), chloroquine 
diphosphate (C6628), colchicine (C9754) 
and vinblastine (V1377) were purchased 
from Sigma-Aldrich (www.sigmaal-
drich.com). Anti-LC3B (L7543), p62 
(P0067) and actin (A2066) polyclonal 
antibodies were purchased from Sigma-
Aldrich, anti-phospho-S6 (ser235/236) 
(2211S) and p70 S6K (9202L) polyclonal 
antibodies were purchased from Cell 
Signaling Technology (www.cellsignal.
com) and anti-Lamp2 (SC-18822) was 
purchased from Santa Cruz (www.scbt.
com). All other reagents were purchased 
from Sigma-Aldrich. Skeletal muscle his-
tochemistry was performed as previously 
described.10
In vivo electroporation. Mice were 
anesthetized using pentobarbital (50 mg 
per kg body weight). The skin overly-
ing the tibialis anterior (TA) muscle was 
shaved, and the animals were injected 
with 25 mg endotoxin free mCherry-GFP-
LC3 expression plasmid (provided by Dr. 
Abhinav Diwan, Washington University) 
diluted in sterile PBS to a volume of 50 
ml by using a 0.5 ml syringe fitted with a 
29-gauge needle. Two-needle array elec-
trodes (450121) (Harvard Apparatus, 
Holliston, MA) were inserted into the 
muscle immediately after DNA delivery 
for electroporation. The distance between 
the electrodes was 5 mm, and the array 
was inserted longitudinally relative to 
the muscle fibers. In vivo electroporation 
parameters were the following: voltage, 
75 V; pulse length, 50 ms; # of pulse, 6 
pulses; pulse interval, 200 msec; desired 
field strength, 200 V/cm, given by a BTX 
ECM830 Electro Square Porator. Animals 
were allowed to recover for 5 days at which 
time they were treated with i.p. vehicle or 
0.4 mg/kg/day colchicine for two days. 
Following treatment, TA muscle was 
harvested and frozen in liquid nitrogen 
cooled isopentane. 10 mM sections of TA 
muscle were affixed to slides, treated for 10 
minutes in ice cold acetone and mounted 
with Prolong Gold + DAPI (Invitrogen; 
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